Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics

Expert Review of Neurotherapeutics

Volumn 17, Issue 1, 2017, Pages 17-32

  Deardorff, William James ^a   Grossberg, George T ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; anti inflammatory agents; immune system; inflammation; neuroinflammation; non steroidal anti inflammatory drug (NSAID)

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; ANTIOXIDANT; CD33 ANTIGEN; CENTRAL STIMULANT AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RETINOID X RECEPTOR AGONIST; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ASTROCYTE; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PHAGOCYTOSIS; PRIMARY PREVENTION; REGULATORY T LYMPHOCYTE; REVIEW; INFLAMMATION; PATHOPHYSIOLOGY; RISK;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INFLAMMATION; RISK;

EID: 85004038637     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1080/14737175.2016.1200972     Document Type: Review

References (142)

1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 2016;12(4):459–509.
2. McGeer PL, McGeer E, Rogers J, et al. Anti-inflammatory drugs and Alzheimer disease. Lancet. 1990;335:1037.
3. Hardy JA, Higgins GA., Alzheimer’s disease:the amyloid cascade hypothesis. Science. 1992;256:184–185.
4. Wyss-Coray T. Inflammation in Alzheimer disease:driving force, bystander or beneficial response? Nat Med. 2006;12(9):1005–1015.
5. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405.
6. Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell. 2013;153(3):707–720.
7. Weitz TM, Town T. Microglia in Alzheimer’s disease:it’s all about context. Int J Alzheimers Dis. 2012;2012:314185.
8. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization:nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20.
9. Mandrekar S, Jiang Q, Lee CY, et al. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci. 2009;29(13):4252–4262.
10. Guillot-Sestier MV, Town T. Innate immunity in Alzheimer’s disease:a complex affair. CNS Neurol Disord Drug Targets. 2013;12(5):593–607.
11. Floden AM, Combs CK. Microglia demonstrate age-dependent interaction with amyloid-beta fibrils. J Alzheimers Dis. 2011;25(2):279–293.
12. Bhaskar K, Maphis N, Xu G, et al. Microglial derived tumor necrosis factor-alpha drives Alzheimer’s disease-related neuronal cell cycle events. Neurobiol Dis. 2014;62:273–285.
13. Guo H, Callaway JB, Ting JP. Inflammasomes:mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677–687.
14. Thal DR. The role of astrocytes in amyloid beta-protein toxicity and clearance. Exp Neurol. 2012;236(1):1–5.
15. Bhat R, Crowe EP, Bitto A, et al. Astrocyte senescence as a component of Alzheimer’s disease. PLoS One. 2012;7(9):e45069.
16. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease:a review of 17 epidemiologic studies. Neurology. 1996;47(2):425–432.
17. Hoozemans JJ, Rozemuller JM, Van Haastert ES, et al. Cyclooxygenase-1 and −2 in the different stages of Alzheimer’s disease pathology. Curr Pharm Des. 2008;14(14):1419–1427.
18. Yasojima K, Schwab C, McGeer EG, et al. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 1999;830(2):226–236.
19. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease:epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28(5):639–647.
20. Choi SH, Bosetti F. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY). 2009;1(2):234–244.
21. Kotilinek LA, Westerman MA, Wang Q, et al. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain. 2008;131(Pt 3):651–664.
22. Woodling NS, Andreasson KI. Untangling the web:toxic and protective effects of neuroinflammation and PGE2 signaling in Alzheimer’s disease. ACS Chem Neurosci. 2016;7(4):454–463.
23. Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage. Curr Top Med Chem. 2008;8(1):47–53.
24. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112(3):440–449.
25. Hirohata M, Ono K, Naiki H, et al. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. Neuropharmacology. 2005;49(7):1088–1099.
26. Avramovich Y, Amit T, Youdim MB. Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J Biol Chem. 2002;277(35):31466–31473.
27. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82–86.
28. Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272(6):3406–3410.
29. Sastre M, Dewachter I, Landreth GE, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci. 2003;23(30):9796–9804.
30. Sastre M, Dewachter I, Rossner S, et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A. 2006;103(2):443–448.
31. Chen CH, Zhou W, Liu S, et al. Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol. 2012;15(1):77–90.
32. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease:systematic review and meta-analysis of observational studies. Bmj. 2003;327(7407):128.
33. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease:a systematic review. Neuroepidemiology. 2004;23(4):159–169.
34. De Craen AJ, Gussekloo J, Vrijsen B, et al. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol. 2005;161(2):114–120.•• Meta-analysis that challenges some of the views of other meta-analyses. This paper provides a good discussion of the biases inherent in epidemiologic studies.
35. Szekely CA, Town T, Zandi PP. NSAIDs for the chemoprevention of Alzheimer’s disease. Subcell Biochem. 2007;42:229–248.
36. Szekely CA, Green RC, Breitner JC, et al. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology. 2008;70(24):2291–2298.
37. Wang J, Tan L, Wang HF, et al. Anti-inflammatory drugs and risk of Alzheimer’s disease:an updated systematic review and meta-analysis. J Alzheimers Dis. 2015;44(2):385–396.
38. Hayden KM, Zandi PP, Khachaturian AS, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology. 2007;69(3):275–282.
39. Waldstein SR, Wendell CR, Seliger SL, et al. Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging. J Am Geriatr Soc. 2010;58(1):38–43.
40. Grodstein F, Skarupski KA, Bienias JL, et al. Anti-inflammatory agents and cognitive decline in a bi-racial population. Neuroepidemiology. 2008;30(1):45–50.
41. Buckley T, Corcoran C, Schwartz S, et al. NSAID use does not affect dementia progression or survival in Alzheimer’s disease. The Cache County dementia progression study. Alzheimers Dement. 2011;7(4):S367.
42. Wichmann MA, Cruickshanks KJ, Carlsson CM, et al. NSAID use and incident cognitive impairment in a population-based cohort. Alzheimer Dis Assoc Disord. 2016;30(2):105–112.
43. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology. 1993;43(8):1609–1611.
44. De Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with indomethacin on Alzheimer’s disease progression:a randomized controlled trial. PLoS One. 2008;3(1):e1475.
45. Pasqualetti P, Bonomini C, Dal Forno G, et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease. Aging Clin Exp Res. 2009;21(2):102–110.
46. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression:a randomized controlled trial. JAMA. 2003;289(21):2819–2826.
47. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204–1215.•• Large study involving patients with mild cognitive impairment.
48. Reines SA, Block GA, Morris JC, et al. Rofecoxib:no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66–71.
49. Advisory Committee Briefing Document Celecoxib and Valdecoxib Cardiovascular Safety. FDA.gov. [cited 2015 Mar6].Available from: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_03_Pfizer-Celebrex-Bextra.pdf
50. Soininen H, West C, Robbins J, et al. Long-term efficacy and safety of celecoxib in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2007;23(1):8–21.
51. Small GW, Siddarth P, Silverman DH, et al. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss:randomized controlled study. Am J Geriatr Psychiatry. 2008;16(12):999–1009.
52. Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology. 1999;53(1):197–201.
53. Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer’s disease. Neurology. 2002;58(7):1050–1054.
54. Gomez-Isla T, Blesa R, Boada M, et al. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment:the TRIMCI study. Alzheimer Dis Assoc Disord. 2008;22(1):21–29.
55. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s disease cooperative study. Neurology. 2000;54(3):588–593.
56. Van Gool WA, Weinstein HC, Scheltens P, et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease:an 18-month randomised, double-blind, placebo-controlled study. Lancet. 2001;358(9280):455–460.
57. Alzheimer Disease:Phase 2 Trial Results Reported by Immune Network Ltd. The Free Library [cited 2016 Mar6]. Available from: http://www.thefreelibrary.com/Alzheimer Disease:Phase 2 Trial Results Reported by Immune Network…-a092852880
58. Wilcock GK, Black SE, Hendrix SB, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease:a randomised phase II trial. Lancet Neurol. 2008;7(6):483–493.
59. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease:a randomized controlled trial. JAMA. 2009;302(23):2557–2564.• Failed phase III study of tarenflurbil, which showed promise in phase II studies.
60. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease:OmegAD study:a randomized double-blind trial. Arch Neurol. 2006;63(10):1402–1408.
61. Pomponi MF, Gambassi G, Pomponi M, et al. Why docosahexaenoic acid and aspirin supplementation could be useful in women as a primary prevention therapy against Alzheimer’s disease? Ageing Res Rev. 2011;10(1):124–131.
62. Jaturapatporn D, Isaac MG, McCleery J, et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev. 2012;2:CD006378.
63. Mazereeuw G, Lanctot KL, Chau SA, et al. Effects of omega-3 fatty acids on cognitive performance:a meta-analysis. Neurobiol Aging. 2012;33(7):1482, e1417–1429.
64. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease:a randomized trial. JAMA. 2010;304(17):1903–1911.
65. Burckhardt M, Herke M, Wustmann T, et al. Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev. 2016;4:CD009002.
66. ADAPT Research Group, Lyketsos CG, Breitner JC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007; 68(21):1800–1808.•• Initial results of the ADAPT primary prevention trial.
67. ADAPT Research Group, Martin BK, Szekely C, et al. Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT):results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65(7):896–905.
68. Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimers Dement. 2011;7(4):402–411.
69. ADAPT-FS Research Group. Follow-up evaluation of cognitive function in the randomized Alzheimer’s disease anti-inflammatory prevention trial and its follow-up study. Alzheimers Dement. 2015;11(2):216–225e211.• Results of the ADAPT follow-up study, which reports data on cognitive measures.
70. ADAPT Trial Research Group. Results of a follow-up study to the randomized Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement. 2013;9(6):714–723.
71. Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition:a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013;88(11):1213–1221.
72. Kandiah N, Feldman HH. Therapeutic potential of statins in Alzheimer’s disease. J Neurol Sci. 2009;283(1–2):230–234.
73. McGuinness B, Craig D, Bullock R, et al. Statins for the treatment of dementia. Cochrane Database Syst Rev. 2014;7:CD007514.
74. Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients (SIMaMCI). ClinicaTrials.gov. [updated 2009 Feb 11; cited 2016 Mar6]. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT00842920
75. Campoy S, Sierra S, Suarez B, et al. Semisynthesis of novel monacolin J derivatives:hypocholesterolemic and neuroprotective activities. J Antibiot (Tokyo). 2010;63(8):499–505.
76. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112(3):440–449.
77. Imbimbo BP. Why did tarenflurbil fail in Alzheimer’s disease? J Alzheimers Dis. 2009;17(4):757–760.
78. Imbimbo BP, Giardino L, Sivilia S, et al. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis. 2010;20(1):159–173.
79. Porrini V, Lanzillotta A, Branca C, et al. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. Neuroscience. 2015;302:112–120.
80. Ross J, Sharma S, Winston J, et al. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment:a 12-week, double-blind, placebo-controlled study. Curr Alzheimer Res. 2013;10(7):742–753.
81. Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J Neurosci. 2012;32(30):10117–10128.
82. Liu J, Wang LN, Jia JP. Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer’s disease and amnestic mild cognitive impairment:a systematic review and meta-analysis. Drugs Aging. 2015;32(1):57–65.
83. Cheng H, Shang Y, Jiang L, et al. The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer’s disease and mild-to-moderate Alzheimer’s disease:a meta-analysis. Int J Neurosci. 2016;126(4):299–307.
84. Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer’s Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW). ClinicalTrials.gov. [updated 2013 Aug 25; cited 2016 Mar6]. Available from: https://clinicaltrials.gov/ct2/show/NCT01931566
85. Tong M, Deochand C, Didsbury J, et al. T3D-959:A multi-faceted disease remedial drug candidate for the treatment of Alzheimer’s disease. J Alzheimer’s Dis. 2016;51:123–138.
86. Feasibility Study in Subjects With Mild to Moderate Alzheimer’s Disease. ClinicalTrails.gov. [updated 2015 Jul 28; cited 2016 Mar6]. Available from:https://clinicaltrials.gov/ct2/show/NCT02560753
87. Kummer MP, Schwarzenberger R, Sayah-Jeanne S, et al. Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits. Mol Neurobiol. 2015;51(2):661–671.
88. Zhao J, Fu Y, Liu CC, et al. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway. J Biol Chem. 2014;289(16):11282–11292.
89. Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science. 2012;335(6075):1503–1506.
90. Cummings JL, Zhong K, Kinney JW, et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease. Alzheimers Res Ther. 2016;8(1):4.
91. Zhao HF, Li N, Wang Q, et al. Resveratrol decreases the insoluble Abeta1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats. Neuroscience. 2015;310:641–649.
92. Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85(16):1383–1391.
93. Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurol. 2008;8:27.
94. Butchart J, Brook L, Hopkins V, et al. Etanercept in Alzheimer disease:A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015;84(21):2161–2168.
95. Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer’s Disease. ClinicalTrials.gov. [updated 2012 Oct 5; cited 2016 Mar6]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01716637
96. Alam JJ. Selective Brain-Targeted Antagonism of p38 MAPKalpha reduces hippocampal IL-1beta levels and improves morris water maze performance in aged rats. J Alzheimers Dis. 2015;48(1):219–227.
97. Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer’s Disease (AD) or Mild AD. ClinicalTrials.gov. [updated 2015 Apr 3; cited 2016 Mar6]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02423200
98. Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674–678.
99. Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–255.
100. Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines:from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719–729.
101. Vom Berg J, Prokop S, Miller KR, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat Med. 2012;18(12):1812–1819.
102. Hu WT, Holtzman DM, Fagan AM, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012;79(9):897–905.
103. Town T, Laouar Y, Pittenger C, et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med. 2008;14(6):681–687.
104. Tesseur I, Zou K, Esposito L, et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer’s pathology. J Clin Invest. 2006;116(11):3060–3069.
105. Guillot-Sestier MV, Doty KR, Town T. Innate immunity fights Alzheimer’s disease. Trends Neurosci. 2015;38(11):674–681.
106. Chakrabarty P, Li A, Ceballos-Diaz C, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron. 2015;85(3):519–533.
107. Baruch K, Deczkowska A, Rosenzweig N, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease. Nat Med. 2016;22(2):135–137.• Pre-clinical report on the effect of PD-1 inhibitors in Alzheimer’s disease.
108. Baruch K, Rosenzweig N, Kertser A, et al. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer’s disease pathology. Nat Commun. 2015;6:7967.
109. Dansokho C, Ait Ahmed D, Aid S, et al. Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain. 2016;139(4):1237–1251.
110. Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283–294.
111. Olmos-Alonso A, Schetters ST, Sri S, et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. Brain. 2016;139(Pt 3):891–907.
112. Spangenberg EE, Lee RJ, Najafi AR, et al. Eliminating microglia in Alzheimer’s mice prevents neuronal loss without modulating amyloid-beta pathology. Brain. 2016;139(4):1265–1281.
113. Lian H, Yang L, Cole A, et al. NFkappaB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer’s disease. Neuron. 2015;85(1):101–115.
114. Lian H, Litvinchuk A, Chiang AC, et al. Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of Alzheimer’s disease. J Neurosci. 2016;36(2):577–589.
115. Mathieu MC, Sawyer N, Greig GM, et al. The C3a receptor antagonist SB 290157 has agonist activity. Immunol Lett. 2005;100(2):139–145.
116. Borroni E, Wyler R, Messer J, et al. Preclinical characterization of RO4602522, a novel, selective and orally active monoamine oxidase type B inhibitor for the treatment of Alzheimer’s disease. Alzheimers Dement. 2013;9(4):P818.
117. Nave S, Doody RS, Boada Rovira M, et al. Sembragiline in moderate Alzheimer’s disease dementia:results of a Phase 2 trial (Mayflower Road). J Prev Alz Dis. 2015;2(4):276–277.
118. Leinenga G, Gotz J. Scanning ultrasound removes amyloid-beta and restores memory in an Alzheimer’s disease mouse model. Sci Transl Med. 2015;7(278):278ra233.
119. Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160(6):1061–1071.
120. Jiang T, Tan L, Zhu XC, et al. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2014;39(13):2949–2962.
121. Jay TR, Miller CM, Cheng PJ, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med. 2015;212(3):287–295.
122. Jiang T, Wan Y, Zhang YD, et al. TREM2 overexpression has no improvement on neuropathology and cognitive impairment in aging APPswe/PS1dE9 mice. Mol Neurobiol. 2016.doi:10.1007/s12035-016-9704-x. [Epub ahead of print]
123. Colonna M, Wang Y. TREM2 variants:new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016;17:201–207.• Good overview paper of the role of TREM2 in AD pathogenesis, which is currently under investigation. This paper provides thorough mechanistic explanations.
124. Wang Y, Ulland TK, Ulrich JD, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213(5):667–675.
125. Yuan P, Condello C, Keene CD, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90(4):724–739.
126. Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78(4):631–643.
127. Fang F, Lue LF, Yan S, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. Faseb J. 2010;24(4):1043–1055.
128. Galasko D, Bell J, Mancuso JY, et al. Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. Neurology. 2014;82(17):1536–1542.
129. Burstein AH, Grimes I, Galasko DR, et al. Effect of TTP488 in patients with mild to moderate Alzheimer’s disease. BMC Neurol. 2014;14:12.
130. Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer’s Disease (STEADFAST). ClinicalTrials.gov. [updated 2014 Feb 25; cited 2016 Mar6]. Available from: https://www.clinicaltrials.gov/show/NCT02080364
131. Salas M, Hofman A, Stricker BH. Confounding by indication:an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999;149(11):981–983.
132. Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer’s disease:the epidemiological evidence. CNS Neurol Disord Drug Targets. 2010;9(2):132–139.
133. In T’ Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med. 2001;345(21):1515–1521.
134. Vlad SC, Miller DR, Kowall NW, et al. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008;70(19):1672–1677.•• A large-scale case-control study on the use of NSAIDs and incidence of Alzheimer’s disease in the Veterans Affair Health Care system.
135. Breitner JC, Haneuse SJ, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009;72(22):1899–1905.
136. Arvanitakis Z, Grodstein F, Bienias JL, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology. 2008;70(23):2219–2225.
137. Szekely CA, Breitner JC, Fitzpatrick AL, et al. NSAID use and dementia risk in the cardiovascular health study:role of APOE and NSAID type. Neurology. 2008;70(1):17–24.
138. Haag MD, Van Oijen M, De Jong FJ, et al. Amyloid β42-level lowering non-steroidal anti-inflammatory drugs and the risk of Alzheimer’s disease. Alzheimers Dement. 2006;2(Suppl1):S43.
139. Cornelius C, Fastbom J, Winblad B, et al. Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology. 2004;23(3):135–143.
140. Puhl AC, Milton FA, Cvoro A, et al. Mechanisms of peroxisome proliferator activated receptor gamma regulation by non-steroidal anti-inflammatory drugs. Nucl Recept Signal. 2015;13:e004.
141. FDA Drug Safety Communication:FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. U.S. Food and Drug Administration [cited 2016 Mar6]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm451800.htm
142. Wang J, Logovinsky V, Hendrix SB, et al. ADCOMS:a composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry. 2016. doi:10.1136/jnnp-2015-312383. [Epub ahead of print]